SAT0018 Inflammatory Cytokines and Autoantibodies Discriminate Between Different Stages of Rheumatoid Arthritis: A Strategy for Classification
BackgroundRheumatoid arthritis (RA) is characterized by inflammation and circulating autoantibodies. Inflammatory cytokines and autoantibodies had been described as important molecules in the immunopathogenesis of the disease. However, whether inflammatory cytokines and autoantibodies together can d...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2015-06, Vol.74 (Suppl 2), p.655 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Suppl 2 |
| container_start_page | 655 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 74 |
| creator | Castañeda-Delgado, J.E. Macias-Segura, N. Santiago-Algarra, D. Castillo, J. Alemán-Navarro, A.L. Martínez-Tejada, P. García-De Lira, Y. Olgín-Calderόn, D. Enciso-Moreno, L. Bastián-Hernández, Y. Ramos-Remus, C.R. Enciso-Moreno, J.A. |
| description | BackgroundRheumatoid arthritis (RA) is characterized by inflammation and circulating autoantibodies. Inflammatory cytokines and autoantibodies had been described as important molecules in the immunopathogenesis of the disease. However, whether inflammatory cytokines and autoantibodies together can discriminate between early RA, chronic RA and preclinical stages is currently unknown.ObjectivesTo evaluate the levels of the cytokines IL-1, IL-6, TNF, IL-8, IL12p70 and IL-10 and the autoantibodies RF and antibodies to cyclic citrullinated peptides (ACCP) to determine the expression differences between humans with clinical and preclinical stages of RA.MethodsSerum from patients with less than 2 years of diagnosis, eRA (n=10) and patients with chronic RA with more than 2 years with the disease (cRA; n=10) were collected. All cRA patients had received treatment with DMARD's. Serum sample from eRA patients treated for 4 months were collected for comparison as well (n=6). First-degree relatives of patients with RA were stratified in positive (ACCP+; n=12) or negative (ACCP-; n=12) to ACCP. Subjects without family history of autoimmune diseases were included in a healthy control group (HC; n=10). Serum levels of ACCP were evaluated using ELISA and RF was measured by nephelometry. Cytokines levels for each group were quantified by BD™ cytometric bead array in a FACS CANTO II. Statistical analysis for group comparisons was done using the Kruskal-Wallis or wilcoxon test for non-parametric data. p |
| doi_str_mv | 10.1136/annrheumdis-2015-eular.5365 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901779000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322501987</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1270-87ddcb8db1beaa96c924d750bbc92237fe482c289417f52431829cf88de165c13</originalsourceid><addsrcrecordid>eNqVkU1PwyAcxonRxDn9DiQ7V6GvVE-1vi1ZYuLmmdAWNmYLE2hMb168-xn9JFLnwasn4MnzPH_gB8AMo3OMo_SCKWU2vO8aaYMQ4STgfcvMeRKlyQGY4DglXk7RIZgghKIgztPsGJxYu_VHRDCZgM9lsUIIk6_3j7kSLes65rQZYDk4_SIVt5CpBha900w5WelGeulG2trITirmOLzm7o1z5UUhuOHKwaVja-_SAj6Nl_OF0lcYtzHSSXsJC-8wProeoNAGli2zVgpZMye1OgVHgrWWn_2uU_B8d7sqH4LF4_28LBZBhcMMBSRrmroiTYUrzlie1nkYN1mCqsrvwigTPCZhHZI8xplIwjjCJMxrQUjDcZrUOJqC2b53Z_Rrz62jW90b5UdSnCOcZfn4ZVNwtXfVRltruKA7_3BmBooRHRHQPwjoiID-IKAjAp9O9-mq2_4r-A3tY5Wb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901779000</pqid></control><display><type>article</type><title>SAT0018 Inflammatory Cytokines and Autoantibodies Discriminate Between Different Stages of Rheumatoid Arthritis: A Strategy for Classification</title><source>BMJ Journals - NESLi2</source><creator>Castañeda-Delgado, J.E. ; Macias-Segura, N. ; Santiago-Algarra, D. ; Castillo, J. ; Alemán-Navarro, A.L. ; Martínez-Tejada, P. ; García-De Lira, Y. ; Olgín-Calderόn, D. ; Enciso-Moreno, L. ; Bastián-Hernández, Y. ; Ramos-Remus, C.R. ; Enciso-Moreno, J.A.</creator><creatorcontrib>Castañeda-Delgado, J.E. ; Macias-Segura, N. ; Santiago-Algarra, D. ; Castillo, J. ; Alemán-Navarro, A.L. ; Martínez-Tejada, P. ; García-De Lira, Y. ; Olgín-Calderόn, D. ; Enciso-Moreno, L. ; Bastián-Hernández, Y. ; Ramos-Remus, C.R. ; Enciso-Moreno, J.A.</creatorcontrib><description>BackgroundRheumatoid arthritis (RA) is characterized by inflammation and circulating autoantibodies. Inflammatory cytokines and autoantibodies had been described as important molecules in the immunopathogenesis of the disease. However, whether inflammatory cytokines and autoantibodies together can discriminate between early RA, chronic RA and preclinical stages is currently unknown.ObjectivesTo evaluate the levels of the cytokines IL-1, IL-6, TNF, IL-8, IL12p70 and IL-10 and the autoantibodies RF and antibodies to cyclic citrullinated peptides (ACCP) to determine the expression differences between humans with clinical and preclinical stages of RA.MethodsSerum from patients with less than 2 years of diagnosis, eRA (n=10) and patients with chronic RA with more than 2 years with the disease (cRA; n=10) were collected. All cRA patients had received treatment with DMARD's. Serum sample from eRA patients treated for 4 months were collected for comparison as well (n=6). First-degree relatives of patients with RA were stratified in positive (ACCP+; n=12) or negative (ACCP-; n=12) to ACCP. Subjects without family history of autoimmune diseases were included in a healthy control group (HC; n=10). Serum levels of ACCP were evaluated using ELISA and RF was measured by nephelometry. Cytokines levels for each group were quantified by BD™ cytometric bead array in a FACS CANTO II. Statistical analysis for group comparisons was done using the Kruskal-Wallis or wilcoxon test for non-parametric data. p<0.05 was considered significant. LDA analysis was performed to evaluate the capacity of the cytokines and autoantibodies to differentiate between groups.ResultsSerum was available from 54 subjects (74% women). Differences between groups were evaluated. All the healthy subjects (HC, ACCP- and ACCP+) were negative to RF. There were significant differences between levels of ACCP between patients and healthy subjects. We found significant differences (p<0.01) in serum concentration of IL-6, TNF-α and IL-10 between patients with RA (eRA and cRA) and the groups HC, ACCP- and ACCP+. IL-1β. There were significant differences (p<0.01) only between cRA and HC in levels of IL-8. The levels of IL-12p70 present significant differences only between eRA and relatives positive and negative to ACCP. LDA analysis demonstrates that using the levels of IL-6, IL-10, ACCP and RF together, 60% can be discriminated among healthy groups with low risk (HC and ACCP-) subjects with high risk (ACCP+), patients with early RA and patients with chronic RA. A 90% of subjects with chronic and early RA can be discriminated as patients, using the expression values of these cytokines and autoantibodies (IL-6, IL-10, ACCP and RF).ConclusionsTogether, levels of ACCP, RF, IL-6 and IL-10 can discriminate the patients with early or chronic onset of RA and preclinical stages including the high-risk subjects. This strategy would improve the diagnosis, treatment and classification for RA patients.Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2015-eular.5365</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.655</ispartof><rights>2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2015 (c) 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/74/Suppl_2/655.3.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/74/Suppl_2/655.3.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77343,77374</link.rule.ids></links><search><creatorcontrib>Castañeda-Delgado, J.E.</creatorcontrib><creatorcontrib>Macias-Segura, N.</creatorcontrib><creatorcontrib>Santiago-Algarra, D.</creatorcontrib><creatorcontrib>Castillo, J.</creatorcontrib><creatorcontrib>Alemán-Navarro, A.L.</creatorcontrib><creatorcontrib>Martínez-Tejada, P.</creatorcontrib><creatorcontrib>García-De Lira, Y.</creatorcontrib><creatorcontrib>Olgín-Calderόn, D.</creatorcontrib><creatorcontrib>Enciso-Moreno, L.</creatorcontrib><creatorcontrib>Bastián-Hernández, Y.</creatorcontrib><creatorcontrib>Ramos-Remus, C.R.</creatorcontrib><creatorcontrib>Enciso-Moreno, J.A.</creatorcontrib><title>SAT0018 Inflammatory Cytokines and Autoantibodies Discriminate Between Different Stages of Rheumatoid Arthritis: A Strategy for Classification</title><title>Annals of the rheumatic diseases</title><description>BackgroundRheumatoid arthritis (RA) is characterized by inflammation and circulating autoantibodies. Inflammatory cytokines and autoantibodies had been described as important molecules in the immunopathogenesis of the disease. However, whether inflammatory cytokines and autoantibodies together can discriminate between early RA, chronic RA and preclinical stages is currently unknown.ObjectivesTo evaluate the levels of the cytokines IL-1, IL-6, TNF, IL-8, IL12p70 and IL-10 and the autoantibodies RF and antibodies to cyclic citrullinated peptides (ACCP) to determine the expression differences between humans with clinical and preclinical stages of RA.MethodsSerum from patients with less than 2 years of diagnosis, eRA (n=10) and patients with chronic RA with more than 2 years with the disease (cRA; n=10) were collected. All cRA patients had received treatment with DMARD's. Serum sample from eRA patients treated for 4 months were collected for comparison as well (n=6). First-degree relatives of patients with RA were stratified in positive (ACCP+; n=12) or negative (ACCP-; n=12) to ACCP. Subjects without family history of autoimmune diseases were included in a healthy control group (HC; n=10). Serum levels of ACCP were evaluated using ELISA and RF was measured by nephelometry. Cytokines levels for each group were quantified by BD™ cytometric bead array in a FACS CANTO II. Statistical analysis for group comparisons was done using the Kruskal-Wallis or wilcoxon test for non-parametric data. p<0.05 was considered significant. LDA analysis was performed to evaluate the capacity of the cytokines and autoantibodies to differentiate between groups.ResultsSerum was available from 54 subjects (74% women). Differences between groups were evaluated. All the healthy subjects (HC, ACCP- and ACCP+) were negative to RF. There were significant differences between levels of ACCP between patients and healthy subjects. We found significant differences (p<0.01) in serum concentration of IL-6, TNF-α and IL-10 between patients with RA (eRA and cRA) and the groups HC, ACCP- and ACCP+. IL-1β. There were significant differences (p<0.01) only between cRA and HC in levels of IL-8. The levels of IL-12p70 present significant differences only between eRA and relatives positive and negative to ACCP. LDA analysis demonstrates that using the levels of IL-6, IL-10, ACCP and RF together, 60% can be discriminated among healthy groups with low risk (HC and ACCP-) subjects with high risk (ACCP+), patients with early RA and patients with chronic RA. A 90% of subjects with chronic and early RA can be discriminated as patients, using the expression values of these cytokines and autoantibodies (IL-6, IL-10, ACCP and RF).ConclusionsTogether, levels of ACCP, RF, IL-6 and IL-10 can discriminate the patients with early or chronic onset of RA and preclinical stages including the high-risk subjects. This strategy would improve the diagnosis, treatment and classification for RA patients.Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkU1PwyAcxonRxDn9DiQ7V6GvVE-1vi1ZYuLmmdAWNmYLE2hMb168-xn9JFLnwasn4MnzPH_gB8AMo3OMo_SCKWU2vO8aaYMQ4STgfcvMeRKlyQGY4DglXk7RIZgghKIgztPsGJxYu_VHRDCZgM9lsUIIk6_3j7kSLes65rQZYDk4_SIVt5CpBha900w5WelGeulG2trITirmOLzm7o1z5UUhuOHKwaVja-_SAj6Nl_OF0lcYtzHSSXsJC-8wProeoNAGli2zVgpZMye1OgVHgrWWn_2uU_B8d7sqH4LF4_28LBZBhcMMBSRrmroiTYUrzlie1nkYN1mCqsrvwigTPCZhHZI8xplIwjjCJMxrQUjDcZrUOJqC2b53Z_Rrz62jW90b5UdSnCOcZfn4ZVNwtXfVRltruKA7_3BmBooRHRHQPwjoiID-IKAjAp9O9-mq2_4r-A3tY5Wb</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Castañeda-Delgado, J.E.</creator><creator>Macias-Segura, N.</creator><creator>Santiago-Algarra, D.</creator><creator>Castillo, J.</creator><creator>Alemán-Navarro, A.L.</creator><creator>Martínez-Tejada, P.</creator><creator>García-De Lira, Y.</creator><creator>Olgín-Calderόn, D.</creator><creator>Enciso-Moreno, L.</creator><creator>Bastián-Hernández, Y.</creator><creator>Ramos-Remus, C.R.</creator><creator>Enciso-Moreno, J.A.</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201506</creationdate><title>SAT0018 Inflammatory Cytokines and Autoantibodies Discriminate Between Different Stages of Rheumatoid Arthritis: A Strategy for Classification</title><author>Castañeda-Delgado, J.E. ; Macias-Segura, N. ; Santiago-Algarra, D. ; Castillo, J. ; Alemán-Navarro, A.L. ; Martínez-Tejada, P. ; García-De Lira, Y. ; Olgín-Calderόn, D. ; Enciso-Moreno, L. ; Bastián-Hernández, Y. ; Ramos-Remus, C.R. ; Enciso-Moreno, J.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1270-87ddcb8db1beaa96c924d750bbc92237fe482c289417f52431829cf88de165c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Castañeda-Delgado, J.E.</creatorcontrib><creatorcontrib>Macias-Segura, N.</creatorcontrib><creatorcontrib>Santiago-Algarra, D.</creatorcontrib><creatorcontrib>Castillo, J.</creatorcontrib><creatorcontrib>Alemán-Navarro, A.L.</creatorcontrib><creatorcontrib>Martínez-Tejada, P.</creatorcontrib><creatorcontrib>García-De Lira, Y.</creatorcontrib><creatorcontrib>Olgín-Calderόn, D.</creatorcontrib><creatorcontrib>Enciso-Moreno, L.</creatorcontrib><creatorcontrib>Bastián-Hernández, Y.</creatorcontrib><creatorcontrib>Ramos-Remus, C.R.</creatorcontrib><creatorcontrib>Enciso-Moreno, J.A.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Family Health Database (Proquest)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database (ProQuest)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Castañeda-Delgado, J.E.</au><au>Macias-Segura, N.</au><au>Santiago-Algarra, D.</au><au>Castillo, J.</au><au>Alemán-Navarro, A.L.</au><au>Martínez-Tejada, P.</au><au>García-De Lira, Y.</au><au>Olgín-Calderόn, D.</au><au>Enciso-Moreno, L.</au><au>Bastián-Hernández, Y.</au><au>Ramos-Remus, C.R.</au><au>Enciso-Moreno, J.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SAT0018 Inflammatory Cytokines and Autoantibodies Discriminate Between Different Stages of Rheumatoid Arthritis: A Strategy for Classification</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2015-06</date><risdate>2015</risdate><volume>74</volume><issue>Suppl 2</issue><spage>655</spage><pages>655-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundRheumatoid arthritis (RA) is characterized by inflammation and circulating autoantibodies. Inflammatory cytokines and autoantibodies had been described as important molecules in the immunopathogenesis of the disease. However, whether inflammatory cytokines and autoantibodies together can discriminate between early RA, chronic RA and preclinical stages is currently unknown.ObjectivesTo evaluate the levels of the cytokines IL-1, IL-6, TNF, IL-8, IL12p70 and IL-10 and the autoantibodies RF and antibodies to cyclic citrullinated peptides (ACCP) to determine the expression differences between humans with clinical and preclinical stages of RA.MethodsSerum from patients with less than 2 years of diagnosis, eRA (n=10) and patients with chronic RA with more than 2 years with the disease (cRA; n=10) were collected. All cRA patients had received treatment with DMARD's. Serum sample from eRA patients treated for 4 months were collected for comparison as well (n=6). First-degree relatives of patients with RA were stratified in positive (ACCP+; n=12) or negative (ACCP-; n=12) to ACCP. Subjects without family history of autoimmune diseases were included in a healthy control group (HC; n=10). Serum levels of ACCP were evaluated using ELISA and RF was measured by nephelometry. Cytokines levels for each group were quantified by BD™ cytometric bead array in a FACS CANTO II. Statistical analysis for group comparisons was done using the Kruskal-Wallis or wilcoxon test for non-parametric data. p<0.05 was considered significant. LDA analysis was performed to evaluate the capacity of the cytokines and autoantibodies to differentiate between groups.ResultsSerum was available from 54 subjects (74% women). Differences between groups were evaluated. All the healthy subjects (HC, ACCP- and ACCP+) were negative to RF. There were significant differences between levels of ACCP between patients and healthy subjects. We found significant differences (p<0.01) in serum concentration of IL-6, TNF-α and IL-10 between patients with RA (eRA and cRA) and the groups HC, ACCP- and ACCP+. IL-1β. There were significant differences (p<0.01) only between cRA and HC in levels of IL-8. The levels of IL-12p70 present significant differences only between eRA and relatives positive and negative to ACCP. LDA analysis demonstrates that using the levels of IL-6, IL-10, ACCP and RF together, 60% can be discriminated among healthy groups with low risk (HC and ACCP-) subjects with high risk (ACCP+), patients with early RA and patients with chronic RA. A 90% of subjects with chronic and early RA can be discriminated as patients, using the expression values of these cytokines and autoantibodies (IL-6, IL-10, ACCP and RF).ConclusionsTogether, levels of ACCP, RF, IL-6 and IL-10 can discriminate the patients with early or chronic onset of RA and preclinical stages including the high-risk subjects. This strategy would improve the diagnosis, treatment and classification for RA patients.Disclosure of InterestNone declared</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2015-eular.5365</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.655 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_proquest_journals_1901779000 |
| source | BMJ Journals - NESLi2 |
| title | SAT0018 Inflammatory Cytokines and Autoantibodies Discriminate Between Different Stages of Rheumatoid Arthritis: A Strategy for Classification |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T07%3A24%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SAT0018%E2%80%85Inflammatory%20Cytokines%20and%20Autoantibodies%20Discriminate%20Between%20Different%20Stages%20of%20Rheumatoid%20Arthritis:%20A%20Strategy%20for%20Classification&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Casta%C3%B1eda-Delgado,%20J.E.&rft.date=2015-06&rft.volume=74&rft.issue=Suppl%202&rft.spage=655&rft.pages=655-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2015-eular.5365&rft_dat=%3Cproquest_cross%3E4322501987%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901779000&rft_id=info:pmid/&rfr_iscdi=true |